Verona pushes on with COPD drug after £70m fundraiser

08:28 EDT 8 Aug 2017 | pharmaphorum

UK biotech Verona Pharma has said it is continuing with development of its chronic obstructive pulmonary disease (COPD) drug after raising £70 million through an IPO and private investment. Verona is developing PRL554, a first-in-class inhaled du...

Original Article: Verona pushes on with COPD drug after £70m fundraiser


More From BioPortfolio on "Verona pushes on with COPD drug after £70m fundraiser"

Quick Search

Relevant Topics

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

COPD (chronic obstructive pulmonary disease)
COPD (chronic obstructive pulmonary disease) is used for a number of conditions including chronic bronchitis and emphysema, which all  lead to the airways in the lungs becoming damaged and thus narrower,  making inhalation and exhalation harder...

Asthma COPD Cystic Fibrosis Pneumonia Pulmonary Medicine Respiratory Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs.  They're usually caused by viruses, but they can also ...